A realistic analysis of the criteria used by rheumatologists in evaluating the progress of patients suffering from rheumatoid arthritis must be based on actual clinical judgments rather than on expressed opinions. A randomly selected 15% sample of British rheumatologists (48) recorded judgements on the progress of 50 'paper' patients, based on data taken from actual patients participating in clinical trials. The rheumatologists differed markedly in their assessffients of the progress of disease, with serious disagreements even when only 'clinically impirtant' changes were considered. Some clinicians showed little consistency in their judgments of duplicate cases. Multiple regression analysis of the patient data in relation to the disease assessments provided a model of each clinician's judgment policy. These judgment policy models showed that the differences in clinical assessment were greater than could be explained by the inconsistent application of similar assessment policies, and were a consequence also of differences in the underlying judgment policies themselves. Judgments related more closely to changes in ESR and other process measures than to changes in functional ability. 
Rheumatologists in Britain' and North America2 advocate many criteria for assessing changes in the clinical status of patients with rheumatoid arthritis (RA), and most investigators collect large quantities of information about their patients.3 4 However, little is known about which criteria are actually used by clinicians in evaluating their patients' progress.
It has proved possible to develop mathematical models of the way rheumatologists judge current disease activity in RA5 6 using 'paper patients'-a convenient technique developed for presenting standard patient data to several doctors on different occasionsI 7-and judgment analysis-a form of multivariate analysis of the information on which decisions are based.5 8 9 These models of judgment policy differed markedly not only from each other Accepted for publication 11 April 1984. Correspondence to Dr J. R. Kirwan but also from the policies clinicians claimed to be using.5
A realistic view of the way physicians assess patients' response to therapy must therefore be based on actual judgments rather than expressed opinions. Such an analysis, by making underlying judgment policies more explicit, may clarify differences in the assessment of particular patients and would allow rational discussion of their importance and implications.9 An understanding of judgment policies is also necessary for the design of soundly based clinical investigations in RA.6 W therefore decided to discover how British rheumatologists judge the success or failure of treatment.
Material and methods
A representative sample of British rheumatologists was asked to assess improvement or deterioration in 50 paper patients, and policy models were calculated (for each rheumatologist) from these judgments. Values were recorded before and after one year of treatment with an unspecified 'second-line' agent. (Fig. 4) . Although some were highly consistent, as shown by a high correlation, others were not. Indeed, those of the two physicians with r<O-4 did Table 4 . The variance in judgments explained by each model ranges from 35% to 97%, and for 36 models R was greater than 0*7, indicating that 50% or more of the variance was satisfactorily accounted for by the model. Twenty-two of the 48 had an R of 0-8 or more, indicating that the models accounted for at least two-thirds of the variance. The mean relative contribution of each clinical variable for all respondents taken together is given in the last row of Table 4 . Demographic analysis of policies. Three major groups of rheumatologists were suggested by cluster analysis of the respondents' demographic data. These differed significantly (p<0-001), as shown Table 5 . The four major clinical variables in the mean policy models of each of these groups are also shown. Although each model includes grip strength and ESR, they differ in the inclusion of early morning stiffness, patient's global assessment, articular index, and aspirin consumption. Separate analysis of those who were authors of any papers in the journals reviewed compared with those who published none showed no significant differences in the mean policy models of each group. Similarly, there were no differences in consistency (r) between these two groups, nor in the ability of the regression equations to model judgments (R2).
Cluster analysis ofpolicy models. Cluster analysis was performed *on all the policy models taken together in order to seek possible natural groupings rather than superimposed clusters, such as those defined by the respondents' demographic data. Those clinical variables contributing 10% or more to the mean policy model of each of the three clusters which emerged are shown in Table 6 . The differences between the models (p<0001) are concen- Rheumatologists' judgments of disease progress proved to be extremely variable. This variability might have been related to differences in the use of a VAS. However, though judgments for 'clinical importance' of any changes used a scale of only three categories, thus providing a much more restricted range of interpretations, the large differences in judgments remained. In addition the policy models were calculated independently for each physician and thus related specifically to his or her own use of the VAS, independently of the way in which the scale was used by others. Nevertheless these models also showed a wide variation between rheumatologists.
Cluster analysis was used to group respondents according to their demographic details or directly in relation to their policy models. The resultant groupings, though tested for significance after they were identified, are considered in broad terms only in order to avoid overinterpretation of complex statistical techniques. Difference in policy models bore some relationship to demographic characteristics. While grip strength and ESR were common to all three groups identified, a combination of geography and appointment separated those who relate their judgments to 'patient centred' assessments (EMS, patients global assessment) from those who use more 'doctor oriented' assessments (NSAID comsumption, articular index). The former group tend to hold appointments in district general hospitals in provincial towns, while the latter includes a high proportion of academic and teaching hospital appointees.
When groupings were sought within all the policy models taken together, three slightly different clusters emerged (Table 6 ). All share the ESR as an important variable, and it has been suggested17-20 that this may be related to long-term outcome in RA, particularly the development of radiographic erosions. In contrast, functional capacity does not appear in any of the cluster policies and was present with a contribution of 10% or more in the policy models of only four doctors. This finding may reflect a recognised preoccupation with measures of disease process rather than disease outcome.2 610
The major clinical disagreements identified in this report are greater than could be explained by the inconsistent application of similar approaches to assessment by different clinicians. They are also a consequence of differences in the clinicians' underlying judgment policies. The explicit definition of policy models should help to reduce inconsistency in their application and thus improve agreement.8 21 
